ARTICLE | Management Tracks
Plus: Heather Turner to lead neurology play LB, and updates from Mirai Bio and Diakonos
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
November 20, 2024 1:02 AM UTC
Latigo Biotherapeutics Inc. appointed Timothy Walbert chair, succeeding Nancy Stagliano who will remain on the board. Walbert was chairman, president and CEO of Horizon Therapeutics Inc., which Amgen Inc. (NASDAQ:AMGN) acquired for $28.3 billion. Latigo is developing Nav1.8-targeting small molecules.
LB Pharmaceuticals Inc. hired CEO Heather Turner to succeed co-founder Zachary Prensky. Turner, who will join Prensky on LB’s board, was president and CEO of Carmot Therapeutics Inc. LB is developing antipsychotics for schizophrenia…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654259/latigo-names-timothy-walbert-chair